Effect of dexamethasone supplementation on chondrogenesis of equine mesenchymal stem cells

• DOI: 10.2460/ajvr.69.8.1013
• Publication Date: 2008-08-01T12:15:37Z
• Authors: Allison A. Stewart; Christopher R. Byron; Holly C. Pondenis; Matthew C. Stewart
• Keywords: Aggrecan; Chondrogenesis; Pellet

Abstract Objective —To determine whether expansion of equine mesenchymal stem cells (MSCs) by use fibroblast growth factor-2 (FGF-2) prior to supplementation with dexamethasone during the chondrogenic pellet culture phase would increase chondrocytic matrix markers without stimulating a hypertrophic phenotype. Sample Population —MSCs obtained from 5 young horses. Procedures —First-passage monolayer MSCs were supplemented medium containing FGF-2 (0 or 100 ng/mL). Confluent transferred cultures and maintained in 0 10 −7 M dexamethasone. Pellets collected after 1, 7, 14 days analyzed for collagen type II protein content; total glycosaminoglycan DNA alkaline phosphatase (ALP) activity; mRNA aggrecan, II, ALP, elongation factor-1α. Results —Treatment FGF-2, dexamethasone, both increased content, expression aggrecan. The content MSC control pellets decreased over time. Treatment prevented loss Pellet ALP activity treated FGF-2–dexamethasone. After data standardized on basis only FGF-2–dexamethasone remained significantly increased. Conclusions Clinical Relevance —Dexamethasone enhanced differentiation MSCs, primarily through an numbers. stimulated mRNA, consistent progression cartilage toward bone. This may be important MSC-based repair articular cartilage.